-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Drop in Short Interest
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Drop in Short Interest
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 36,800 shares, a decrease of 16.0% from the November 15th total of 43,800 shares. Currently, 0.4% of the company's stock are sold short. Based on an average daily trading volume, of 36,900 shares, the days-to-cover ratio is presently 1.0 days.
Analyst Ratings Changes
CADL has been the subject of several recent research reports. HC Wainwright initiated coverage on Candel Therapeutics in a report on Friday, December 2nd. They set a "buy" rating and a $11.00 price target for the company. Credit Suisse Group decreased their price target on Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Wednesday, December 7th.
Get Candel Therapeutics alerts:Candel Therapeutics Stock Performance
NASDAQ:CADL traded down $0.24 during trading on Friday, reaching $1.65. The company's stock had a trading volume of 145,640 shares, compared to its average volume of 35,939. The firm has a market cap of $47.68 million, a price-to-earnings ratio of -3.93 and a beta of 0.18. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.41 and a current ratio of 13.41. The firm has a 50 day moving average of $1.92 and a 200-day moving average of $2.89. Candel Therapeutics has a 12 month low of $1.47 and a 12 month high of $8.70.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in CADL. Citadel Advisors LLC purchased a new position in shares of Candel Therapeutics during the 3rd quarter valued at $53,000. BlackRock Inc. lifted its position in shares of Candel Therapeutics by 15.5% during the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company's stock valued at $674,000 after buying an additional 17,708 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Candel Therapeutics during the 2nd quarter valued at $2,408,000. Hedge funds and other institutional investors own 21.97% of the company's stock.About Candel Therapeutics
(Get Rating)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Further Reading
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Candel Therapeutics, Inc. (NASDAQ:CADL – Get Rating) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 36,800 shares, a decrease of 16.0% from the November 15th total of 43,800 shares. Currently, 0.4% of the company's stock are sold short. Based on an average daily trading volume, of 36,900 shares, the days-to-cover ratio is presently 1.0 days.
坎德爾治療公司(納斯達克代碼：CADL-GET評級)是11月份空頭股數大幅下降的目標。截至11月30日，空頭股數共有3.68萬股，較11月15日的4.38萬股減少16.0%。目前，該公司0.4%的股票被賣空。以日均成交量36,900股計算，目前天數與回補比率為1.0天。
Analyst Ratings Changes
分析師評級發生變化
CADL has been the subject of several recent research reports. HC Wainwright initiated coverage on Candel Therapeutics in a report on Friday, December 2nd. They set a "buy" rating and a $11.00 price target for the company. Credit Suisse Group decreased their price target on Candel Therapeutics from $10.00 to $8.00 and set an "outperform" rating for the company in a report on Wednesday, December 7th.
CADL是最近幾份研究報告的主題。HC Wainwright在12月2日星期五的一份報告中開始了對Candel治療公司的報道。他們為該公司設定了“買入”評級和11.00美元的目標價。瑞士信貸集團將Candel Treeutics的目標價從10.00美元下調至8.00美元，並在12月7日星期三的一份報告中為該公司設定了“跑贏大盤”的評級。
Candel Therapeutics Stock Performance
Candel Treeutics股票表現
NASDAQ:CADL traded down $0.24 during trading on Friday, reaching $1.65. The company's stock had a trading volume of 145,640 shares, compared to its average volume of 35,939. The firm has a market cap of $47.68 million, a price-to-earnings ratio of -3.93 and a beta of 0.18. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.41 and a current ratio of 13.41. The firm has a 50 day moving average of $1.92 and a 200-day moving average of $2.89. Candel Therapeutics has a 12 month low of $1.47 and a 12 month high of $8.70.
納斯達克：CADL在週五的交易中下跌0.24美元，至1.65美元。該公司股票的成交量為145,640股，而其平均成交量為35,939股。該公司市值為4768萬美元，本益比為-3.93倍，貝塔係數為0.18。該公司的負債權益比率為0.40，速動比率為13.41，流動比率為13.41。該公司的50日移動均線切入位在1.92美元，200日移動均線切入位在2.89美元。Candel Treeutics的12個月低點為1.47美元，12個月高位為8.70美元。
Institutional Inflows and Outflows
機構資金流入和流出
About Candel Therapeutics
關於秋茄治療公司
(Get Rating)
(獲取評級)
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Candel Treateutics，Inc.是一家臨床階段的生物製藥公司，致力於為癌症患者開發免疫療法。該公司開發了CAN-2409，目前正處於治療胰腺癌的第二階段臨床試驗；治療前列腺癌的第三階段臨床試驗；以及治療肺癌的第二階段臨床試驗，以及治療高級別膠質瘤的Ib/II階段臨床試驗。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Candel Therapeutics (CADL)
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- This is no Time to Buy Lennar but the Time is Coming
- 免費獲取StockNews.com關於Candel治療(CADL)的研究報告
- MarketBeat：回顧一週12/12-12/16
- 哪兩家藍籌科技公司提高了他們的指引？
- 你應該擔心埃隆·馬斯克出售他持有的特斯拉股票嗎？
- 拖拉機庫存能否突破杯柄收購點？
- 現在不是購買Lennar的時候，但時機即將到來
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《秋茄治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Candel Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧